FY2025 · period end Dec '25 · from the 10-K filed Feb 25, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $6.07B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Figures a later SEC filing revised by more than 0.5% from what was originally reported. Each diff compares the same XBRL tag across two filings, so you can open both and check it yourself.
Operating Income (Loss)
Q2 2023
Revised down 19.5% — reported in a 10-Q.
As first reported
$327.2MAs it stands now
$263.5MIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Q2 2023
Revised down 18.7% — reported in a 10-Q.
As first reported
$338.5MAs it stands now
$275.1MIncome (Loss) from Continuing Operations before Income Taxes, Foreign
FY 2022
Revised down 17.6% — reported in a 10-K.
As first reported
$1.1BAs it stands now
$933.5MRevenue from Contract with Customer, Excluding Assessed Tax
FY 2022
Revised down 17.1% — reported in a 10-K.
As first reported
$5.4BAs it stands now
$4.5BAny P/S built on the original filing understated the true multiple by 20.6% — and stayed wrong from Feb 13, 2023 to Feb 28, 2025.
Revenue from Contract with Customer, Excluding Assessed Tax
Q1 2024
Revised down 16.8% — reported in a 10-Q.
As first reported
$1.6BAs it stands now
$1.3BAny P/S built on the original filing understated the true multiple by 20.2% — and stayed wrong from Apr 29, 2024 to May 6, 2025.
Income (Loss) from Continuing Operations before Income Taxes, Domestic
FY 2023
Revised down 16.6% — reported in a 10-K.
As first reported
$348MAs it stands now
$290.1MRestatements are detected by comparing every vintage of a fact across all of Edwards Lifesciences Corp's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows EW's most significant revisions, and a figure absent from it has not been certified as unrevised.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001099800-26-000028 | May 7, 2026 | May 8, 2026 | May 8, 2026 20:12 UTC | EDGAR |
| 10-Q | 0001099800-26-000026 | Mar 31, 2026 | May 6, 2026 | May 6, 2026 20:12 UTC | EDGAR |
| 8-K | 0001099800-26-000023 | May 2, 2026 | May 4, 2026 | May 4, 2026 20:53 UTC | EDGAR |
| 8-K | 0001099800-26-000021 | Apr 23, 2026 | Apr 23, 2026 | Apr 23, 2026 20:20 UTC | EDGAR |
| 10-K | 0001099800-26-000009 | Dec 31, 2025 | Feb 25, 2026 | Feb 25, 2026 21:11 UTC | EDGAR |
| 8-K | 0001099800-26-000006 | Feb 10, 2026 | Feb 10, 2026 | Feb 10, 2026 21:22 UTC | EDGAR |
| 8-K | 0001099800-26-000002 | Jan 9, 2026 | Jan 12, 2026 | Jan 9, 2026 23:51 UTC | EDGAR |
| 10-Q | 0001099800-25-000062 | Sep 30, 2025 | Nov 5, 2025 | Nov 5, 2025 21:12 UTC | EDGAR |
Direct links to SEC EDGAR. EW has additional filings available on the SEC site.
Who is buying and selling Edwards Lifesciences Corp — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on EW yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on EW and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $5.01B |
| $4.46B |
| $5.23B |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B |
|---|
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B |
|---|
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
|---|
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
|---|
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B |
| Stockholders' Equity | $10.34B | $10.06B | $6.72B | $5.81B | $5.84B |
| Cash & Equivalents | $2.94B | $3.06B | $1.15B | $0.77B | $0.87B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.60B | $0.54B | $0.90B | $1.22B | $1.73B |
| Capital Expenditures | $0.26B | $0.25B | $0.25B | $0.24B | $0.33B |
| Free Cash Flow | $1.33B | $0.29B | $0.64B | $0.97B | $1.41B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% |
| Operating Margin | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% |
| Net Margin | 0.2% | 0.8% | 0.3% | 0.3% | 0.3% |
| Return on Equity | 10.5% | 49.8% | 22.4% | 26.1% | 28.9% |
| Return on Assets | 8.0% | 37.2% | 15.9% | 18.1% | 19.1% |
| Debt / Equity | 0.06× | 0.06× | 0.09× | 0.10× | 0.10× |
